Trial Profile
A Phase 2 Study of Pazopanib (GW786034) in Patients With Advanced and Progressive Malignant Pheochromocytoma or Paraganglioma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Paraganglioma; Phaeochromocytoma
- Focus Therapeutic Use
- 22 May 2015 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
- 01 Apr 2014 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.
- 15 Jan 2014 Status changed from recruiting to active, no longer recruiting; according to M.D. Anderson Cancer Center record.